본문
SEOUL, Korea – L&C Bio (KOSDAQ: 290650) announced on the 25th that its human tissue-derived knee cartilage treatment, MegaCarti®, will be available by prescription beginning next month.
According to a recent announcement by the Ministry of Health and Welfare, MegaCarti® has been approved for clinical use under the New Health Technology Assessment (nHTA) Deferment Program from May 1, 2025 through September 30, 2025.
MegaCarti® is the world’s first medical device developed to regenerate hyaline cartilage using human tissue. The product is directly implanted into damaged cartilage areas to provide structural support, enabling rapid pain relief and accelerating recovery through autologous cartilage regeneration.
Developed through a government-backed pan-ministry medical device development program, MegaCarti® has demonstrated excellence across multiple evaluation stages. It has resulted in three published clinical papers, domestic and international patent applications and registrations, successful clinical trials, regulatory approval, prototype production, and commercialization—with high ratings from expert institutions.
CEO Hwan-Chul Lee stated:
“Even during the deferment period, we plan to gather additional clinical evidence beyond the approved data to support MegaCarti®’s global expansion efforts.”
